Immunotherapy for head and neck squamous cell carcinoma

Memo - Magazine of European Medical Oncology

Volumn 9, Issue 2, 2016, Pages 66-69

  Fuereder, Thorsten ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

checkpoint inhibitor; head and neck squamous cell carcinoma; immunotherapy; PD 1; PDL 1

Indexed keywords

CD134 ANTIGEN; CD28 ANTIGEN; CD39 ANTIGEN; CETUXIMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOCETAXEL; DURVALUMAB; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; IPILIMUMAB; METHOTREXATE; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; TALIMOGENE LAHERPAREPVEC; TICILIMUMAB; TRANSFORMING GROWTH FACTOR BETA;

CANCER IMMUNOTHERAPY; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD56+ CYTOTOXIC NATURAL KILLER CELL; CD8+ T LYMPHOCYTE; CELL INFILTRATION; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FOXP3+ T LYMPHOCYTE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOCOMPETENT CELL; MACROPHAGE; MYELOID DEPRESSOR CELL; PNEUMONIA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR ESCAPE;

EID: 84975248863     PISSN: 18655041     EISSN: 18655076     Source Type: Journal    
DOI: 10.1007/s12254-016-0270-8     Document Type: Review

References (27)

1. Mapara MY, Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol. 2004;22:1136–51. doi:10.1200/jco.2004.10.041.
2. Muenst S, et al. The immune system and cancer evasion strategies: therapeutic concepts. J Intern Med. 2016; doi:10.1111/joim.12470.
3. Gillison ML. Oropharyngeal cancer: a potential consequence of concomitant HPV and HIV infection. Curr Opin Oncol. 2009;21:439–44. doi:10.1097/CCO.0b013e32832f3e1b.
4. http://image.slidesharecdn.com/tumourclasss-110703094237-phpapp02/95/tumourclasss-26-728.jpg?cb=1309686256. Accesed: 13.6.2016
5. Ferris RL. Immunology and immunotherapy of head and neck cancer. J Clin Oncol. 2015;33:3293–304. doi:10.1200/jco.2015.61.1509.
6. Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2004;10:3755–62. doi:10.1158/1078–0432.ccr-04-0054.
7. Nguyen N, et al. Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. Head Neck. 2016; doi:10.1002/hed.24406.
8. Dasgupta S, Bhattacharya-Chatterjee M, O’Malley BW. Inhibition of NK cell activity through TGF-beta 1 by down-regulation of NKG2D in a murine model of head and neck cancer. J Immunol. 2005;175:5541–50.
9. Kloss S, et al. Increased sMICA and TGFbeta levels in HNSCC patients impair NKG2D-dependent functionality of activated NK cells. Oncoimmunology. 2015;4:e1055993 doi:10.1080/2162402x.2015.1055993.
10. Wagner S, et al. CD56-positive lymphocyte infiltration in relation to human papillomavirus association and prognostic significance in oropharyngeal squamous cell carcinoma. Int J Cancer. 2016;138:2263–73. doi:10.1002/ijc.29962.
11. Shang B, Liu Y, Jiang SJ, Liu Y. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep. 2015;5:15179 doi:10.1038/srep15179.
12. Badoual C, et al. Prognostic value of tumor-infiltrating CD4+ T‑cell subpopulations in head and neck cancers. Clin Cancer Res. 2006;12:465–72. doi:10.1158/1078-0432.ccr-05-1886.
13. Lalami Y, Awada A. Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice. Cancer Treat Rev. 2016;43:113–23. doi:10.1016/j.ctrv.2016.01.001.
14. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–9. doi:10.1038/nature10673.
15. http://labiotech.eu/pfizer-merck-ovarian-cancer-trial-avelumab-pdl1-immunooncology/. Accesed: 13.6.2016
16. Zandberg DP, Strome SE. The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncol. 2014;50:627–32. doi:10.1016/j.oraloncology.2014.04.003.
17. Parikh F, et al. Chemoradiotherapy-induced upregulation of PD-1 antagonizes immunity to HPV-related oropharyngeal cancer. Cancer Res. 2014; doi:10.1158/0008-5472.can-14-1913.
18. Concha-Benavente F, et al. Identification of the cell-intrinsic and -extrinsic pathways downstream of EGFR and IFNgamma that induce PD-L1 expression in head and neck cancer. Cancer Res. 2016;76:1031–43. doi:10.1158/0008-5472.can-15-2001.
19. Agrawal N, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011;333:1154–7. doi:10.1126/science.1206923.
20. Jie HB, et al. CTLA-4(+) regulatory T cells increased in cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis. Cancer Res. 2015;75:2200–10. doi:10.1158/0008-5472.can-14-2788.
21. Cheng. ASCO 2015, oral presentation.
22. Gillison. AACR 2016, oral presentation.
23. Kohlhapp FJ, Kaufman HL. Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy. Clin Cancer Res. 2016;22:1048–54. doi:10.1158/1078-0432.ccr-15-2667.
24. Brahmer J, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–35. doi:10.1056/NEJMoa1504627.
25. Borghaei H, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–39. doi:10.1056/NEJMoa1507643.
26. Alexandrov LB, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–21. doi:10.1038/nature12477.
27. Yearly. ECCO 2015, oral presentation.